Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Nexstim

9.88 EUR-2.37 %10.9. klo 18.29
5,688 following

NXTMH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-2.37 %
+3.02 %
+8.57 %
+12.53 %
-30.42 %
-23.11 %
+228.24 %
+103.29 %
-98.37 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
79.78M EUR
Turnover
88.5K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
17.08.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Risk
Business risk
Valuation risk
Low
High
All
Research
Press releases
3rd party
ShowingAll content types

Forum discussions
I’ll also throw my two cents into the pile here in this vibe coding arena. I’ve previously played around with my own forecasts in Google Sheets, but since I already use AI for pretty much everything in my work, it was only natural to bring this hobby into the modern age as well. ...
20 hours ago
by Kyhnykeisari
19
BioSpace – 9 Sep 26 Sinaptica Therapeutics to Present at H.C. Wainwright 28th Annual Global... Sinaptica is presenting at the investment conference. According to Mariashin’s comment, patients are already being marched there for a screening study preparing for the pivotal trial. Could...
yesterday
by Jatast
15
BrainsWay published a release on a Deep TMS pilot study in patients with both depression and early Alzheimer’s disease. This is interesting news regarding the cooperation between Nexstim and Sinaptica, but not as relevant as the headline suggests. The study included only 12 patients...
yesterday
by Kyhnykeisari
13
Sinaptica is progressing very well, and you can get quite a lot out of that comment by Mariash from HCW. In July, Mariash described the treatment process (closed-loop): 45 min baseline calibration → MRI → nine points around the precuneus → data to the cloud (9GB/patient) → about ...
22 hours ago
by AccionHombre
12
Erinomainen arvaustyökalu Välillä tulee mallinnettua Nexstimin tulevaisuutta käyttämällä jonkin toisen yrityksen historiaa verrokkina. Esimerkiksi Revenion spekseillä on joskus tullut arvuuteltua Nexstimin mahdollista arvostusta tulevaisuudessa. Eihän noilla mitään tekemistä todellisuuden...
18 hours ago
by Mark_Renton
8
I’ve been calculating and playing with the exact same scenarios using similar mental models. Revenio used to have strong growth, but in my opinion, if sales develop favorably, this is sort of that scenario on steroids. That’s because EPS starts to rise pretty aggressively after a...
16 hours ago
by Informaatio
7
I understand that thought, but all of these companies are such unique beasts that I personally don’t find direct comparison very relevant. I also invested in Revenio back in the day when they were still selling rubber boats and call center services, and Icare was starting to be polished...
14 hours ago
by Kyhnykeisari
5
Read more on our forum
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 17.08.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release04.09.2026 klo 09.00

European University Hospital Orders Nexstim NBS 6 System

Nexstim
Press release03.09.2026 klo 09.00

Nordic Private Clinic Expands Use with Additional NBS 6 System

Nexstim
Third party research02.09.2026 klo 09.11

Nexstim: Stimulating growth with surgical accuracy; INITIATE with BUY - NuWays AG Research

Nexstim is a Finnish MedTech company and a global leader in navigated transcranial magneticstimulation (nTMS) technology. With nTMS, Nexstim helps (i) surgeons preserve patients' motor and speech cortices and (ii) clinicians treat neurological and psychiatric...

Nexstim

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release02.09.2026 klo 09.00

US University Customer Purchases Nexstim NBS 6 for Research Purposes

Nexstim
Press release01.09.2026 klo 09.00

European Hospital Orders Nexstim NBS 6 System

Nexstim
Press release21.08.2026 klo 09.00

Nexstim Receives NBS 6 System Order for a European hospital and existing Nexstim customer

Nexstim
Regulatory press release20.08.2026 klo 13.00

Nexstim Plc: Managers’ Transactions, Weckroth

Nexstim
Press release19.08.2026 klo 09.00

Nexstim Receives NBS 6 Therapy System Order from New US Customer

Nexstim
Nexstim H1'26: Brainlab potential to be weighed later this year
Research17.08.2026 klo 10.09 by
Antti Siltanen

Nexstim H1'26: Brainlab potential to be weighed later this year

Concrete evidence of the Brainlab collaboration's potential will be available during the rest of the year.

Nexstim
Regulatory press release14.08.2026 klo 09.00

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2026 (UNAUDITED)

Nexstim
Press release11.08.2026 klo 09.00

Notice of Nexstim Plc’s Half-Year Report H1 2026

Nexstim
Nexstim H1'26 preview: Our expectations for the beginning of the year are moderate
Analyst Comment11.08.2026 klo 09.25 by
Antti Siltanen

Nexstim H1'26 preview: Our expectations for the beginning of the year are moderate

We expect the dip in recurring revenue to have weighed on earnings.

Nexstim
Press release31.07.2026 klo 13.00

Finnish Private Clinic Group Orders Additional Nexstim NBS 6 System

Nexstim
Regulatory press release20.07.2026 klo 13.00

Nexstim Plc: Disclosure of major holdings under Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim
Press release17.07.2026 klo 09.00

Delve Psychiatry Upgrades to Nexstim's Latest NBS 6 Platform

Nexstim
Press release15.07.2026 klo 09.00

Nexstim Receives NBS 6 Therapy System Order from a Neurology Clinic in the United States

Nexstim
Nexstim received another order for ten NBS 6 systems
Analyst Comment15.07.2026 klo 09.01 by
Frans-Mikael Rostedt

Nexstim received another order for ten NBS 6 systems

The second order for ten systems within a month indicates the rapid scaling of the distribution partnership.

Nexstim
Press release14.07.2026 klo 09.00

Nexstim Receives a New Order for Ten NBS 6 Systems from Distributor

Nexstim
Press release10.07.2026 klo 09.00

Nexstim Receives Expanded Health Canada Approval for NBS 6 Diagnostics and Pain Applications

Nexstim
Press release08.07.2026 klo 09.00

Nexstim Secures First NBS 6 Sale Following Malaysian Market Authorization

Nexstim